Natural Eggshell Membrane: Clinically Effective on Joints

In addition to the primary end points of change in WOMAC, NEM^® was also evaluated for safety. There were no serious adverse events reported during the trial and the treatment was reported to be well-tolerated by study subjects.

Due to the fact the participants where only required to take one 500 mg capsule of NEM^® per day — versus three 500-mg capsules of glucosamine per day — they were generally compliant with the treatment. “I do a fair amount of medical research, and I would say there were very little comments or concerns about the preparation that they were taking,” said Dr. Winkler. “So I think that compliance and lack of side effects was something we saw pretty consistently throughout the trial.”

When the number of pills patients are required to take is increased, absolute compliance is significantly decreased. “If you look at someone who’s on one pill a day, average compliance is about 80%,” Dr. Winkler explained. “If you have someone on two pills a day, it drops down to about 50%. If you have someone on three or more pills a day, it’s more like 20 or 25% in terms of compliance.” Therefore, the fact that NEM^® requires just one capsule per day to achieve clinically relevant reductions in pain and stiffness is a significant benefit.

“We’re thrilled that Clinical Rheumatology has published our study,” said Chris Haynes, National Sales Manager for ESM Technologies. “A lot of companies tout that their joint pain ingredient has been clinically tested, but has their research been accepted for publication in a highly respected journal that’s been reviewed by other medical professionals to ensure it meets current scientific standards? NEM^® has.”

The new study confirms previous research conducted on NEM® and published in the medical journal Clinical Interventions in Aging. Two 30-day open-label human clinical trials had previously shown that NEM^® significantly reduced joint pain and increased range of motion in less than ten days.